Anthony J. Hubbard, Acting President and CFO. Mr. Hubbard has provided executive, financial, and accounting services to founding management teams for over 25 years. He has served in an executive capacity as the Vice President of Finance, Chief Financial Officer, and General Manager. Prior to his position with BVI, he managed business development as a general partner in a small business consulting firm and served as CFO of an emerging biotechnology venture from 1999-2002. He was a partner in a CPA firm that provided business, management, and tax advisory services to entrepreneurial enterprises. He was also co-founder and CEO for an Indiana biotechnology company for six years. He has served on the Board of Directors for a medical device industry trade association and various community groups. Mr. Hubbard is a licensed CPA and earned his B.A. degree in Microbiology and Biological Sciences, as well as an MBA in Finance from Indiana University Kelly School of Business.
Mark A. Suckow, D.V.M., Chief Scientific Officer. Dr. Suckow is Director of the Freimann LIfe Science Center and Associate Research Professor of Biological Sciences at the University of Notre Dame. Dr. Suckow earned his Doctor of Veterinary Medicine from the University of Wisconsin in 1987 and completed a post-doctoral residency program in laboratory animal medicine at the University of Michigan in 1990. He is a Diplomate of the American College of Laboratory Animal Medicine (ACLAM). Dr. Suckow has published over 80 scientific papers, books, and book chapters. In addition, he co-edited The IACUC Handbook (CRC Press 2000 and 2007) and The Laboratory Rat (Elsevier Academic Press, 2006). Dr. Suckow's research focuses on the development of cancer vaccines, vaccine adjuvants, and the relationship of proteins associated with hemostatis in colon carcinoma and other pathologies. Dr. Suckow has served as the President of the American Association for Laboratory Animal Science (AALAS) and is currently on the Board of Directors of the American Society of Laboratory Animal Practitioners (ASLAP). He has been honored with the Young Investigator of the Year by the AALAS and received the Excellence in Research Award from the ASLAP.
Rae D. Record Ritchie, Ph.D., Vice President of Research. Dr. Ritchie has more than 25 years experience in clinical and research laboratories. She has been the lead investigator on grants and research contracts. Her research has resulted in over 25 peer-reviewed publications. Dr. Ritchie's administrative experience includes establishing and maintaining a genetic tissue bank, managing a multi-user facility, and overseeing testing agreements. Dr. Ritchie has supervised technicians as well as mentored and assisted high school students, undergraduates, graduate, medical students, and post-doctoral fellows. Dr. Ritchie has over 10 years experience working with the base material comprising the Matrix Immune Modulator™ (MIM) technology resulting in patents and numerous publications. She has been a member of an external advisory committee for an NIH sponsored program at the University of Peurto Rico and a consultant for biotechnology firms. Dr. Ritchie received her B.S. degree from Purdue University in Medical Technology and her Ph.D. from Texas A&M University.
Amy M. Overby, Vice President of Operations. Ms. Overby has over 15 years of experience in the medical and research fields. She received her B.S. degree in Molecular Biology, Biochemistry, and Bioinformatics from Towson University. She has worked in the Molecular Pathology and Cancer Cytogenetics Department with The Johns Hopkins University School of Medicine prior to joining the Research Department at Cook Biotech, Inc. In 2005, at Cook Biotech, Inc. she was the principal scientist for novel extracellular matrix (ECM) based technologies from research/development phases to manufacturing transfer, including initiating and implementing extensive in vitro and in vivo studies within industry and universities. She managed undergraduates, interns, medical students, and support staff with experimental techniques and laboratory protocols/procedures as well as establishing and maintaining Biosafety Level 2 (BL2) laboratories. Ms. Overby has multiple patents issued and pending as well as, peer-reviewed publications.
Anthony J. Hubbard, Acting President and CFO. Mr. Hubbard has provided executive, financial, and accounting services to founding management teams for over 25 years. He has served in an executive capacity as the Vice President of Finance, Chief Financial Officer, and General Manager. Prior to his position with BVI, he managed business development as a general partner in a small business consulting firm and served as CFO of an emerging biotechnology venture from 1999-2002. He was a partner in a CPA firm that provided business, management, and tax advisory services to entrepreneurial enterprises. He was also co-founder and CEO for an Indiana biotechnology company for six years. He has served on the Board of Directors for a medical device industry trade association and various community groups. Mr. Hubbard is a licensed CPA and earned his B.A. degree in Microbiology and Biological Sciences, as well as an MBA in Finance from Indiana University Kelly School of Business.
Mark A. Suckow, D.V.M., Chief Scientific Officer. Dr. Suckow is Director of the Freimann LIfe Science Center and Associate Research Professor of Biological Sciences at the University of Notre Dame. Dr. Suckow earned his Doctor of Veterinary Medicine from the University of Wisconsin in 1987 and completed a post-doctoral residency program in laboratory animal medicine at the University of Michigan in 1990. He is a Diplomate of the American College of Laboratory Animal Medicine (ACLAM). Dr. Suckow has published over 80 scientific papers, books, and book chapters. In addition, he co-edited The IACUC Handbook (CRC Press 2000 and 2007) and The Laboratory Rat (Elsevier Academic Press, 2006). Dr. Suckow's research focuses on the development of cancer vaccines, vaccine adjuvants, and the relationship of proteins associated with hemostatis in colon carcinoma and other pathologies. Dr. Suckow has served as the President of the American Association for Laboratory Animal Science (AALAS) and is currently on the Board of Directors of the American Society of Laboratory Animal Practitioners (ASLAP). He has been honored with the Young Investigator of the Year by the AALAS and received the Excellence in Research Award from the ASLAP.
Rae D. Record Ritchie, Ph.D., Vice President of Research. Dr. Ritchie has more than 25 years experience in clinical and research laboratories. She has been the lead investigator on grants and research contracts. Her research has resulted in over 25 peer-reviewed publications. Dr. Ritchie's administrative experience includes establishing and maintaining a genetic tissue bank, managing a multi-user facility, and overseeing testing agreements. Dr. Ritchie has supervised technicians as well as mentored and assisted high school students, undergraduates, graduate, medical students, and post-doctoral fellows. Dr. Ritchie has over 10 years experience working with the base material comprising the Matrix Immune Modulator™ (MIM) technology resulting in patents and numerous publications. She has been a member of an external advisory committee for an NIH sponsored program at the University of Peurto Rico and a consultant for biotechnology firms. Dr. Ritchie received her B.S. degree from Purdue University in Medical Technology and her Ph.D. from Texas A&M University.
Amy M. Overby, Vice President of Operations. Ms. Overby has over 15 years of experience in the medical and research fields. She received her B.S. degree in Molecular Biology, Biochemistry, and Bioinformatics from Towson University. She has worked in the Molecular Pathology and Cancer Cytogenetics Department with The Johns Hopkins University School of Medicine prior to joining the Research Department at Cook Biotech, Inc. In 2005, at Cook Biotech, Inc. she was the principal scientist for novel extracellular matrix (ECM) based technologies from research/development phases to manufacturing transfer, including initiating and implementing extensive in vitro and in vivo studies within industry and universities. She managed undergraduates, interns, medical students, and support staff with experimental techniques and laboratory protocols/procedures as well as establishing and maintaining Biosafety Level 2 (BL2) laboratories. Ms. Overby has multiple patents issued and pending as well as, peer-reviewed publications.
